| Type | Public |
| HQ | London, GB |
| Size (employees) | 10 (est) |
| Website | immupharma.org |
Immupharma is headquartered in London, GB
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataImmupharma Office Locations
Immupharma has offices in London, Sarnen and Mulhouse
London, (HQ)
50 Broadway
Mulhouse,
5 Rue du Rhône
Sarnen,
10 Poststrasse
Report incorrect company information
Immupharma Financials and Metrics
Immupharma Revenue
Immupharma's revenue was reported to be £150.46 k in FY, 2017
| GBP | |
|---|---|
Revenue (FY, 2017) | 150.5k |
Net income (FY, 2017) | (6.2m) |
EBITDA (FY, 2017) | (7.1m) |
EBIT (FY, 2017) | (7.2m) |
Cash (31-Dec-2017) | 2.7m |
| GBP | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 25.4k | 63.2k | 57.1k | 22.1m | 32.5k | 16.8k | 184.8k | 76.4k | 164.8k | 150.5k | ||||
Revenue growth, % | (59%) | |||||||||||||
Operating expense total | (1.5m) | 3.6m | 4.6m | 11.8m | 4.2m | (3.8m) | 3.6m | 4.6m | 6.8m | 7.4m | ||||
EBITDA | (2.0m) | (3.5m) | (4.5m) | 10.3m | (4.1m) | 3.9m | (4.1m) | (4.2m) | (3.3m) | (4.4m) | (6.5m) | (7.1m) |
| GBP | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 1.0 | 1.0 | 1.0 | 978.2k | 1.0m | 2.7m | 2.9m | 12.5m | 22.5m | 15.6m | 12.2m | 8.9m | 5.4m | 5.4m | 833.4k | 1.9m | 2.7m |
Accounts Receivable | 3.2k | 22.2k | 2.8k | 13.2k | |||||||||||||
Current Assets | 1.0 | 1.0 | 1.0 | 979.9k | 1.0m | 2.9m | 3.3m | 12.6m | 23.9m | 16.8m | 13.5m | 9.8m | 6.5m | 6.1m | 2.4m | 6.0m | 4.4m |
PP&E | 12.0k | 12.8k | 13.3k | 9.3k | 76.8k | 125.4k | 114.8k | 97.1k | 366.4k | 280.1k | 231.9k | 161.4k |
| GBP | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.4k | 15.1k | (2.5m) | (3.1m) | 4.7m | 8.1m | (2.0m) | (3.4m) | (3.8m) | (3.7m) | (2.9m) | (3.9m) | (5.3m) | (6.2m) |
Cash From Operating Activities | 15.8k | 18.3k | 879.6k | 3.8m | (3.6m) | 12.0m | (6.8m) | (3.4m) | (3.3m) | (3.9m) | (2.5m) | (4.1m) | (6.5m) | (4.4m) |
Cash From Financing Activities | 977.0k | 3.0m | (77.6k) | 12.0m | (143.5k) | 555.2k | 165.3k | 356.9k | 191.5k | 3.0m | (310.1k) | 7.4m | 5.4m | |
Net Change in Cash | 978.2k | 27.1k | 2.7m | 3.7m | 8.5m | 11.9m | (6.4m) | (3.2m) | (2.8m) | (3.7m) | 199.0k | (4.5m) | 896.3k | 945.9k |
| GBP | Y, 2017 |
|---|---|
Revenue/Employee | 15.0k |
Financial Leverage | 1.4 x |
Report incorrect company information
Immupharma Online and Social Media Presence
467 Twitter followers
Immupharma has 467 Twitter Followers. The number of followers has increased 2.1% month over month and increased 5.7% quarter over quarter
Report incorrect company information
Immupharma Blogs
November 01, 2018
Nominated Adviser Status
ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser (“NOMAD”), Northland Capital Partners (“Northland”) with SP Angel Corporate Finance LLP. The Directors have also been inf…
September 26, 2018
Interim results announcement for the six months ended 30 June 2018
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2018 (the “Period”). Key Highlights Lupuzor Lupuzor™ demonstrated a superior response rate over placebo (52.5%…
September 19, 2018
Standford Capital Partners and Si Capital are appointed as joint broker
ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has, with immediate effect, appointed Stanford Capital Partners and SI Capital as joint brokers. They will work in conjunction with Northland Capital Partners who are the Company’s NOMA…
September 07, 2018
IMM September 2018 Corporate Update
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company today announces a corporate update. Click here to view
The post IMM September 2018 Corporate Update appeared first on ImmuPharma.
June 14, 2018
ImmuPharma announces positive pre-clinical data on its CIDP programme
Positive results of P140 (Lupuzor™ or Forigerimod) published in the Journal of Autoimmunity in a model of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The T cell modulator P140 significantly reduced the disease in the murine preclinical model Data provides evidence for the expansion of P…
June 06, 2018
Annual Report and Accounts Posted to Shareholders
Notice of Annual general Meeting on 28 June 2018 @ 10.30 AM Venue: Sky Light City Tower, 50 Basinghall Street, London, EC2 ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended …
Immupharma Company Life and Culture
Report incorrect company information
Immupharma Frequently Asked Questions
How many employees does Immupharma have?
Immupharma has 10 employees.
What is Immupharma revenue?
Latest Immupharma annual revenue is £150.5 k.
What is Immupharma revenue per employee?
Latest Immupharma revenue per employee is £15 k.
Who are Immupharma competitors?
Competitors of Immupharma include myTomorrows, Actinium Pharmaceuticals and MWI Veterinary Supply.
Where is Immupharma headquarters?
Immupharma headquarters is located at 50 Broadway, London.
Where are Immupharma offices?
Immupharma has offices in London, Sarnen and Mulhouse.
How many offices does Immupharma have?
Immupharma has 3 offices.